Azathioprine

Author: Prof. Dr. med. Peter Altmeyer

Last updated on: 29.10.2020

Definition
This section has been translated automatically.

Active substance belonging to the immunosuppressive group (originally developed as a cytostatic drug). Imidazole derivative of 6-mercaptopurine (6MP), which is metabolized in the liver to 6MP by a thiopurine methyltransferase (TPMT) (TPMT has a known polymorphism that can lead to both increased inactivation and increased toxicity of AZT; about 10% of the normal population are heterozygous carriers of an allele with low TPMT activity. In homozygous carriers, AZT can lead to severe myelosuppression). In terms of effect, 100 mg of azathioprine corresponds to about 60 mg of 6MP. Both drugs are degraded as purine analogues (via xanthine oxidase) to uric acid, a metabolic pathway that can be inhibited by allopurinol. Allopurinol causes an accumulation of azathioprine or 6MP with the risk of severe bone marrow toxicity. If purine analogues and allopurinol are administered simultaneously, the dose of azathioprine must therefore be adjusted, see table.

Half-life
This section has been translated automatically.

4,5–5 h

You might also be interested in

Advertisment

Dermatology

Swimming pool granuloma

Atypical mycobacteriosis caused by Mycobacterium marinum.

Pharmacodynamics (Effect)
This section has been translated automatically.

Inhibition of DNA and RNA synthesis, immunosuppression, anti-inflammatory effect, inhibition of humoral and cell-mediated immune response, inhibition of B-cell proliferation as well as IgG and IgM synthesis, suppression of CD4 cells, stimulation of CD8 cells.

Indication
This section has been translated automatically.

Azathioprine is the most frequently used immunosuppressive after glucocorticoids ( glucocorticoids, systemic). Its advantage is that it can be combined with other immunosuppressants, e.g. methotrexate or ciclosporin A.

Absolute indications: Systemic lupus erythematosus, mixed collagenosis (overlap syndrome), polymyositis/dermatomyositis, panarteritis nodosa, pemphigus vulgaris, bullous pemphigoid.
Azathioprine 2nd choice: Wegener's granulomatosis, Behçet's disease, Pyoderma gangraenosum, polymyalgia rheumatica, systemic scleroderma, primary Sjögren's syndrome, rheumatoid arthritis, psoriatic arthritis, juvenile chronic arthritis, essential cryoglobinemia.
Exceptional indications of azathioprine therapy: persistent erythema exsudativum multiforme, ankylosing spondylitis, infectious arthritis (e.g. Lyme arthritis, reactive arthritis), degenerative diseases, fibromyalgia syndrome.

Limited indication
This section has been translated automatically.

Liver and kidney diseases (careful haematological controls, possible dose reduction), Lesch-Nyhan syndrome (reduced efficacy), simultaneous or recently completed cytostatic/myelosuppressive therapy, thiopurine methyltransferase (TMPT) deficiency (rapid onset of myelosuppression). DNA strand breaks can be detected when azathioprine is ingested and exposed to UVA radiation (the azathioprine metabolite 6-thioguanine is incorporated into the cellular DNA where it acts as a UVA-sensitive chromophore!)

Dosage and method of use
This section has been translated automatically.

adults: 1-2,5 mg/kg bw/day p.o.
children from 1 year: 50-150 mg/day p.o.
children from 12 years: 100-200 mg/day p.o.

Remember! The daily dose can be divided into three doses (e.g. 3 times/day 50 mg). The onset of effect can be expected after 3-4 weeks, this is recognizable by a "steroid-saving effect"!

Undesirable effects
This section has been translated automatically.

In the case of severe side effects such as nausea, vomiting, hepatotoxicity, bone marrow depression and mucosal ulcerations, thiopurine-methyltransferase deficiency should be excluded. This enzyme is responsible for the metabolism of azathioprine.

Interactions
This section has been translated automatically.

S. Tab.

Contraindication
This section has been translated automatically.

Severe liver, kidney and bone marrow damage, pancreatitis, vaccinations with live vaccines (mumps, measles, rubella, polio, BCG), severe infections (system mycoses, toxoplasmosis, tuberculosis), pregnancy, lactation, hypersensitivity to the active substance or 6-MP.

Preparations
This section has been translated automatically.

Imurek, Zytrim

Note(s)
This section has been translated automatically.

Remember! During the treatment and up to 6 months afterwards, effective contraception must be carried out on both men and women! Blood tests (BB and liver values) in the 1st month weekly, in the 2nd and 3rd month every 14 days, then monthly!
The therapy can be continued without problems for 4-6 years (after that the risk of hepatocellular carcinoma increases dramatically!)
The degradation product of azathioprine, 6-thioguanine, is incorporated into the DNA and acts as a UVA-sensitive chromophore, which induces chromosome strand breaks upon UVA irradiation (see also DNA repair).
It is recommended to have the TPMT status determined before starting!

Literature
This section has been translated automatically.

Brem R et al (2010) DNA breakage and cell cycle checkpoint abrogation induced by a therapeutic thiopurine and UVA radiation. Oncogene 29:3953-3963
Meggitt SJ et al (2011) Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine. Br J Dermatol 165:711-734.

Tables
This section has been translated automatically.

Side effects of Azathioprine

Airway organs	Alveolitis, dyspnoea, flu-like symptoms, cough, rarely interstitial pneumonia
Blood/lymph	dose-dependent blood formation disorder, leukopenia (up to 50%), thrombopenia, anemia, pancytopenia, eosinophilia, leukocytosis, bleeding tendency, megaloblast anemia (administration of leukoverin!), acute myeloid leukemia, non-Hodgkin's lymphomas (0.5%)
Electrolytes, metabolism, endocrinium	Hyperbilirubinaemia, reticulum cell Ca, breast Ca
GIT	Nausea, vomiting, gastro-intestinal disorders, loss of appetite (12%), diarrhoea (depending on the source: 5-20% of patients).), steatorrhoea, intrahepatic cholestasis with increase of AP, GPT, GOT (reversible), intestinal perforation, diverticulitis, dysphagia, toxic hepatitis (1-5%, reversible after discontinuation), Budd-Chiari syndrome (in kidney transplant patients), pancreatitis (reversible), parotitis, primary hepatocellular carcinoma (after many years of therapy)
Skin	Urticaria (depending on the source: 2-8% of patients), exanthema (2%), alopecia (reversible), mucous membrane ulcers, bacterial skin infections, verrucae vulgaris, herpes zoster and herpes simplex as well as spinocellular carcinomas (especially at higher dosages)
Cardiovascular	cardiac arrhythmia, RR drop, hypotension up to circulatory collapse
Nervous System	Neuritis, paresthesias, rigor, dizziness, worsening of a myasthenia gravis up to myasthenic crisis
Kidney	Renal dysfunction
Other	fever, increased tendency to infections, chromosomal changes (reversible after weaning), teratogenicity
Support apparatus	Arthralgia, arthritis, myalgia, myositis

Interactions of Azathioprine

ACE inhibitors	severe leukopenia
Allopurinol	Azathioprine level ↑, allopurinol effect ↓ (common metabolic pathway via xanthine oxidase)
Live virus vaccines	Risk of atypical reactions, avoid combination
Pancuronium	Pancuronium effect ↓
Penicillamine	Penicillamine toxicity ↑
Suxamethonium	neuromuscular blockage ↑
Inactivated vaccines	Inactivated vaccine effect ↓, immune response ↓
Trimethoprim sulfonamides	Antifolate activity ↑, trimethoprim sulfonamide toxicity ↑, kidney damage
Tubocurarin	Tubocurarin effect ↓